CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Blepharitis - How up-to-date is this topic?
Changes
Version 1.2, revision planned in 2012.
Last revised in May 2008
September 2010 — minor update. Hydromoor® (hypromellose 0.3% preservative-free single dose eye drops) have been included. Issued in September 2010.
March 2010 — minor update. Lubri-Tears® eye ointment has been discontinued. Prescription removed. Issued in March 2010.
December 2007 to May 2008 — converted from PRODIGY guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.
- The clinical scenario structure has been reviewed.
- There have been changes to the oral antibiotic prescriptions offered. Lymecycline has been added to the list of recommended tetracyclines.
- Dosing recommendations for the tetracyclines have been amended; a higher initial dose is recommended for 4 weeks, followed by a lower maintenance dose for a further 8 weeks.
- Prescriptions of amoxicillin and erythromycin to treat acute staphylococcal infection (cellulitis) have been removed because this indication is now outside the scope of this CKS topic. In recognition of this, the age threshold has been increased to 10 years as chronic blepharitis is very rare in young children.
© NHS Institute for Innovation and Improvement